UCI performed no blood tests during Amgen Tour of California

Stage 7 of the 2011 Amgen Tour of California

Stage 7 of the 2011 Amgen Tour of California (Image credit: Jon Devich/Cyclingnews.com/epicimages.us)

A plan to implement a comprehensive and independent anti-doping scheme for the Amgen Tour of California was watered down when a deal to allow the US Anti-doping Agency (USADA) to perform all in-competition testing was scuttled by the sport's governing body. Cyclingnews has learned that no blood controls were performed during the race after the UCI took responsibility for the race-day testing.

Thank you for reading 5 articles in the past 30 days*

Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read any 5 articles for free in each 30-day period, this automatically resets

After your trial you will be billed £4.99 $7.99 €5.99 per month, cancel anytime. Or sign up for one year for just £49 $79 €59

Join now for unlimited access

Try your first month for just £1 / $1 / €1

Daniel Benson

Daniel Benson was the Editor in Chief at Cyclingnews.com between 2008 and 2022. Based in the UK, he joined the Cyclingnews team in 2008 as the site's first UK-based Managing Editor. In that time, he reported on over a dozen editions of the Tour de France, several World Championships, the Tour Down Under, Spring Classics, and the London 2012 Olympic Games. With the help of the excellent editorial team, he ran the coverage on Cyclingnews and has interviewed leading figures in the sport including UCI Presidents and Tour de France winners.